Sparsentan, also known as Filspari, is a drug used to treat primary immunoglobulin A nephropathy (IgA nephropathy). It significantly reduces proteinuria levels and delays disease progression by dual inhibition of endothelin receptor (ETAR) and angiotensin II receptor (AT1R). Spasentan has shown promising efficacy in clinical trials, providing a new treatment option for patients with IgA nephropathy.
Filspari/Sparsentan has a good effect on the treatment of lgA nephropathy
Sparsentan is a dual endothelin and angiotensin II receptor antagonist used primarily for the treatment of primary IgA nephropathy with a risk of rapid disease progression. It significantly improves the prognosis of patients by inhibiting ETAR and AT1R, reducing proteinuria, delaying the deterioration of renal function.
Efficacy of Sparsentan
Sparsentan significantly reduced proteinuria levels in patients with IgA nephropathy in clinical trials. The study showed that patients who used Sparsentan experienced an average reduction in proteinuria levels of 49.8% after 36 weeks of treatment, compared to only 15.1% in the control group. This remarkable efficacy makes it an important option for the treatment of IgA nephropathy.
Indications for Spasentan
Spasentan is indicated for adults with primary IgA nephropathy who are at risk for rapid disease progression and have a urine protein-to-creatinine ratio (UPCR) of ≥1.5 g/g. It helps patients maintain a better quality of life by reducing proteinuria, delaying the deterioration of kidney function.
The efficacy of Sparsentan is significant, but its mechanism of action is complex and involves multiple targets, and we will introduce the targets of Sparsentan.
Targets of Sparsentan
Sparsentan exerts its therapeutic effects by dual inhibition of endothelin receptor (ETAR) and angiotensin II receptor (AT1R). This dual inhibitory effect gives it significant advantages in reducing proteinuria and delaying the deterioration of renal function.
Endothelin receptor (ETAR) inhibition
Endothelin is a potent vasoconstrictor involved in the process of glomerulosclerosis and renal interstitial fibrosis. Sparsentan reduces the pathological effect of endothelin by inhibiting ETAR, thereby protecting renal function and delaying disease progression.
Angiotensin II receptor (AT1R) inhibition
Angiotensin II mediates intraglomerular hypertension and proteinuria through AT1R. Sparsentan slows down the further deterioration of renal function by inhibiting AT1R, reducing intraglomerular pressure and reducing proteinuria.
The mechanism of action of Sparsentan is complex and involves multiple targets, and patients need to adjust the dose according to their own conditions. Next, we will introduce the dose adjustment of Sparsentan in special populations.
Dose adjustment for special populations of Sparsentan
The use of Sparsentan needs to be dosed according to the specific situation of the patient, especially in special populations such as hepatic impairment and pregnant and lactating women. Patients should follow their doctor's instructions strictly when taking medication.
Dose adjustment in patients with hepatic impairment
Sparsentan should be avoided in patients with hepatic impairment (Child-Pugh class A-C). Liver impairment may increase the risk of toxicity of the drug, and patients should have a liver function assessment before use and adjust the dose according to the doctor's recommendations.
Dose adjustment for pregnant and lactating women
Sparsentan is embryo-fetal toxic and contraindicated in pregnant women. Breastfeeding should be avoided during use. Women of reproductive potential should use effective contraception during treatment and for one month after discontinuation.
Sparsentan is a prescription drug, and patients should strictly follow the doctor's instructions when using it and review it regularly to prevent possible serious adverse reactions.
